Chronic Obstructive Pulmonary Disease: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis

  • ID: 3797418
  • Drug Pipelines
  • 549 pages
  • Datamonitor Healthcare
1 of 3
While the chronic obstructive pulmonary disease (COPD) market will see downward pressure from the arrival of generic versions of key marketed brands, new products will drive positive growth during 2015-24.

This report addresses the following questions:

- How will the emergence of numerous long-acting beta 2 agonist/long-acting muscarinic antagonist (LABA/LAMA) combinations and triple combinations impact the gold standard Spiriva?
- Which are the preferred LABA/LAMA combinations among pulmonologists?
- How will triple combination therapies fit into the COPD treatment algorithm?
- What role will administration frequency play in choice of therapy?
- How will the availability of generics affect sales of key marketed drugs?
- What role will biologics play in COPD?
Note: Product cover images may vary from those shown
2 of 3
FORECAST: CHRONIC OBSTRUCTIVE PULMONARY DISEASE

- Executive Summary
- Market Overview and Trends
- Market Definition and Methodology
- Advair (fluticasone/salmeterol)
- Anoro Ellipta (umeclidinium/vilanterol)
- Arcapta (indacaterol)
- Breo (fluticasone furoate/vilanterol)
- CHF 5 (beclometasone/formoterol/glycopyrrolate)
- Daliresp (roflumilast)
- Duaklir Genuair (aclidinium/formoterol)
- Dulera (mometasone/formoterol)
- FF/UMEC/VI (fluticasone/umeclidinium/vilanterol)
- Incruse (umeclidinium)
- Nucala (mepolizumab)
- PT
- (formoterol/glycopyrrolate)
- PT
- (budesonide/glycopyrronium/Formoterol)
- Seebri Breezhaler (glycopyrrolate)
- Spiriva (tiotropium)
- Stiolto Respimat (olodaterol/tiotropium)
- Striverdi Respimat (olodaterol)
- Symbicort (budesonide/formoterol)
- Tudorza Pressair (aclidinium)
- Ultibro (indacaterol/glycopyrronium bromide)
- Primary Research Methodology

TREATMENT: CHRONIC OBSTRUCTIVE PULMONARY DISEASE

- Executive Summary
- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends
- Unmet Needs in Chronic Obstructive Pulmonary Disease
- Pipeline Drugs and Future Treatment

EPIDEMIOLOGY: COPD IN THE US, JAPAN, AND 5EU

- Executive Summary
- Disease Background
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations
- Bibliography

EPIDEMIOLOGY: COPD IN BRAZIL

- Executive Summary
- Disease Background
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations
- Bibliography

MARKETED DRUGS: CHRONIC OBSTRUCTIVE PULMONARY DISEASE

- Executive Summary
- Product Overview
- Other Marketed Drugs for COPD
- Appendix
- Product profile: Advair
- Product profile: Anoro
- Product profile: Arcapta Neohaler
- Product profile: Breo
- Product profile: Daliresp
- Product profile: Duaklir Genuair
- Product profile: Incruse
- Product profile: Seebri Breezhaler
- Product profile: Spiriva
- Product profile: Stiolto Respimat
- Product profile: Striverdi Respimat
- Product profile: Symbicort
- Product profile: Tudorza Pressair
- Product profile: Ultibro

PIPELINE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE

- Executive Summary
- Clinical Pipeline Overview
- Recently Discontinued Drugs
- Appendix
- Product profile (late stage): CHF 59
- Product profile (late stage): FF/UMEC/VI
- Product profile (late stage): Nucala
- Product profile (late stage): PT0
- Product profile (late stage): PT0
- Product profile (late stage): benralizumab
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll